ACELYRIN Faces CFO Resignation and Trial Setback

ACELYRIN, INC. ( (SLRN) ) has issued an announcement.

ACELYRIN, INC. announced the resignation of CFO Gil M. Labrucherie, who will provide consulting services until March 2025. The company’s Phase 2b/3 trial for izokibep in uveitis did not meet its primary endpoint, leading ACELYRIN to cease further investment in the drug. ACELYRIN will continue to focus on its late-stage development of lonigutamab for thyroid eye disease, with a Phase 3 program scheduled for early 2025. Despite the trial setback, the company’s cash reserves are projected to support its operations until mid-2027, allowing for potential pipeline expansion.

More about ACELYRIN, INC.

ACELYRIN, INC. is a late-stage clinical biopharmaceutical company focused on accelerating the development and delivery of transformative medicines in immunology. The company is primarily involved in identifying, acquiring, and commercializing new treatment options, with a lead program featuring lonigutamab, a monoclonal antibody for thyroid eye disease.

YTD Price Performance: -42.49%

Average Trading Volume: 664,114

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $430.4M

Find detailed analytics on SLRN stock on TipRanks’ Stock Analysis page.